Transcription of HIGHLIGHTSOF PRESCRIBINGINFORMATION Hyperglycemia …
{{id}} {{{paragraph}}}
Example: marketing
HIGHLIGHTSOF PRESCRIBINGINFORMATION Hyperglycemia …
HIGHLIGHTS OF PRESCRIBING INFORMATIONT hese highlights do not include all the information needed to use TOUJEO safely andeffectively. See full prescribing information for TOUJEO .TOUJEO (insulin glargine injection) U-300, for subcutaneous useInitial Approval: 2015 RECENT MAJOR CHANGES Dosage and Administration ( , )3/2018 Warnings and Precautions ( , )3/2018 INDICATIONS AND USAGE TOUJEO is a long-acting human insulin analog indicated to improve glycemic control in adults withdiabetes mellitus. (1)Limitations of Use:Not recommended for treating diabetic ketoacidosis. (1) DOSAGE AND ADMINISTRATION Individualize dose based on type of diabetes, metabolic needs, blood glucose monitoringresults and glycemic control goal. ( , , ) Administer subcutaneously once daily at any time during the day, at the same time every day.( ) Rotate injection sites to reduce the risk of lipodystrophy. ( ) Do not dilute or mix with any other insulin or solution.
cutaneous amyloidosis have been reported to result in hyperglycemia, and a sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia [see Adverse Reactions (6)]. Make any changes to a patient’s insulin …
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: